3.0.0 5115 2023-01-13T04:48:45Z 2023-01-13T04:48:45Z House H HR 2006-04-06 109 hswm00 Ways and Means Committee House Standing Referred to 2006-04-06T14:01:50Z 2006-04-06 Referred to the House Committee on Ways and Means. IntroReferral H11100 2 House floor actions hswm00 Ways and Means Committee 2006-04-06 Introduced in House IntroReferral Intro-H 9 Library of Congress 2006-04-06 Introduced in House IntroReferral 1000 9 Library of Congress H001033 Rep. Hart, Melissa A. [R-PA-4] MELISSA HART R PA A. 4 N E000187 Rep. English, Phil [R-PA-3] PHIL ENGLISH R PA 3 2006-04-06 True W000273 Rep. Weller, Jerry [R-IL-11] GERALD WELLER R IL C. 11 2006-04-06 True R000033 Rep. Ramstad, Jim [R-MN-3] JIM RAMSTAD R MN 3 2006-04-27 False Taxation Accounting Biomedical engineering Biotechnology Capital gains tax Charities Clinical trials Commerce Corporate finance Corporation taxes Depreciation and amortization Drug industry Drugs Finance and Financial Sector Foundations Government Operations and Politics Government paperwork Health Hospitals Income tax Influenza Interest Investments Losses Medical innovations Medical research Medical supplies Minimum tax Orphan drugs Pharmaceutical research Real estate development Research and development tax credit Research centers Science, Technology, Communications Scientific instruments and apparatus Small business Social Welfare Stocks Tax credits Tax deductions Tax exclusion Tax incentives Tax-exempt securities Technology transfer Vaccines Valuation Taxation

00 2006-04-06 Introduced in House 2006-05-13T14:15:30Z U.S. Healthcare Technologies Competitiveness Act of 2006 - Amends the Internal Revenue Code to provide tax incentives for investment in biomedical research corporations and related entities, by: (1) exempting investors in biomedical research corporations from limitations on net operating losses acquired through stock sales and mergers involving such corporations; (2) permitting a complete offset against the alternative minimum tax for the net operating losses of biomedical research corporations; (3) making permanent and increasing the rates for the tax credit for increasing research activities; (4) allowing tax credits for countermeasures equity investments and research expenses, qualified medical innovation expenses, equity investments in incubational companies, and investment in qualified biotechnology zone bonds; (5) accelerating eligibility for the tax credit for orphan drug expenses; (6) allowing expensing of biotechnology science park property and medical research equipment; (7) allowing deferral of the tax on gain from the sale of stock in a biomedical research corporation; (8) increasing the tax deductibility of capital losses on the sale of stock in biomedical research corporations; and (9) modifying passive loss deduction rules and S corporation shareholder requirements for biomedical research corporations.

]]>

Display Title Official Title as Introduced Introduced in House IH Short Titles as Introduced Introduced in House 2006-04-06T04:00:00Z https://www.govinfo.gov/content/pkg/BILLS-109hr5115ih/xml/BILLS-109hr5115ih.xml 2006-04-06 Referred to the House Committee on Ways and Means. text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.